Question follow-through · 18898
Obesity: Drugs
To ask the Secretary of State for Health and Social Care, what assessment he has made of variations between integrated care boards in access to weight-loss injections such as tirzepatide for weight management; whether the funding provided to integrated ca
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 14 Jul 2026
- Target answer date
- 16 Jul 2026
- Answer
- 7 Sept 2026 · 55 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
14 Jul 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment he has made of variations between integrated care boards in access to weight-loss injections such as tirzepatide for weight management; whether the funding provided to integrated ca
16 Jul 2026
Target answer date
Date supplied by the official written-questions record.
7 Sept 2026
Answer published
In December 2024, the National Institute for Health and Care Excellence (NICE) recommended tirzepatide, also known as Mounjaro, for managing obesity.In anticipation of the expected demand and the need to deliver treatment safely in primary care, NICE agre...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.